<scp>ECLIPSES</scp>: Early initiation of sodium glucose <scp>cotransporter</scp>‐2 inhibitors for <scp>cardiovascular</scp> protection in patients with type 2 diabetes following acute coronary syndrome and <scp>subsequent</scp> coronary artery bypass
Early initiation of SGLT2i use was not associated with a reduction in MACE in patients with T2DM who experienced ACS and underwent subsequent CABG surgery. However, no apparent safety concerns were identified. Adequately powered trials are required to confirm this finding.
Authors
- Karen L. Then (ORCID: https://orcid.org/0000-0002-1345-3987)
- Erik Youngson (ORCID: https://orcid.org/0000-0002-0654-4469)
- Cheryl Harten
- Meng Lin (ORCID: https://orcid.org/0009-0000-4541-2920)
- Lena Makortoff
- Melissa Dutchak
Institutions
- Alberta Health Services (CA)
- University of Alberta (CA)
- University of Calgary (CA)
Publication Details
- Journal
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1002/phar.4620
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.79